β-AR Agonist and PABRA Regimen for Neurodegenerative Side-Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's, often cause undesirable peripheral side effects, particularly cardiac effects, and there is a need to mitigate these while maintaining therapeutic efficacy.
Innovation Solution
Administering a therapeutically effective amount of a β-AR agonist, such as clenbuterol or tulobuterol, combined with a sub-therapeutic dose of a peripherally acting β-blocker (PABRA), like nadolol or atenolol, to offset these side effects while improving cognitive function and treating neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a β-AR agonist is administered to improve cognitive function and treat neurodegenerative diseases, then cognitive improvement is achieved, but peripheral side effects (particularly cardiac effects) occur
Solution Approach 1:
A peripherally acting β-blocker (PABRA) is introduced as an intermediary substance that selectively blocks peripheral β-adrenergic receptors. This mediator prevents the β-AR agonist from binding to peripheral receptors, thereby eliminating peripheral side effects while allowing the agonist to remain active in the central nervous system for cognitive improvement.
Solution Approach 2:
The PABRA exhibits selective pharmacological activity with high affinity for peripheral β-adrenergic receptors but minimal penetration into the central nervous system. This creates a spatial differentiation of receptor blockade: peripheral receptors are blocked while central receptors remain available for the β-AR agonist, achieving localized effect differentiation.
2Object-affected harmful factors
If a peripherally acting β-blocker is administered to offset peripheral side effects, then peripheral side effects are reduced, but therapeutic efficacy for specific disease indications may be compromised
Solution Approach 1:
The PABRA is administered at a sub-therapeutic dose that is insufficient to produce therapeutic effects on its own but sufficient to block peripheral β-adrenergic receptors. This partial action approach allows selective peripheral blockade without achieving full therapeutic blockade that would compromise the β-AR agonist's efficacy.
Solution Approach 2:
The β-adrenergic receptor system is segmented into central and peripheral compartments. The PABRA acts exclusively in the peripheral compartment, while the β-AR agonist acts in the central compartment. This spatial segmentation allows independent optimization of each compartment's function without interference.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively improves cognitive function and treats neurodegenerative diseases with reduced peripheral side effects, as evidenced by brain imaging techniques like FDG-PET and MRI-ASL, indicating regional metabolic activation and cerebral perfusion improvements.
Implementation Method 1
administering a therapeutically effective amount of β-AR agonist
Implementation Method 2
administering a sub-therapeutic dose of a peripherally acting β-blocker (PABRA) to offset undesirable peripheral side effects
Implementation Method 3
brain imaging techniques like FDG-PET and MRI-ASL, indicating regional metabolic activation
Implementation Method 4
brain imaging techniques like FDG-PET and MRI-ASL, indicating regional metabolic activation and cerebral perfusion improvements
Data Source
AI summary
In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist and a peripherally acting β-blocker (PABRA) to a patient in need thereof.